Not So Different: A Podcast From The Center For Biosimilars

Show notes: To check out part 1 of this interview series (written Q&A with Samsung Bioepis’ Kyung-Ah Kim), click here. Coming soon, part 3 will be a video interview about the initial market response to ophthalmology biosimilars and how industry leaders can work together to increase uptake. To learn more about the approval of Cimerli, click here. To learn more about ophthalmology biosimilars, click here. To learn more about interchangeability, click here. To learn more about clinical efficacy testing, click here. To learn more about our LinkedIn Live event on ophthalmology biosimilars, you can read more here or watch the full discussion here. To check out the FDA’s overview page on biosimilars, click here. To check out the FDA’s patient-focused biosimilar education materials (English and Spanish versions), click here. To check out the FDA’s biosimilar education materials for health care professionals, click here. For more information on the FDA's biosimilar curriculum, click here. For more information o